Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Well-known Drug Has Less Risk for Preterm Delivery in PCOS

By Norwegian University of Science and Technology | April 2, 2019

Metformin can halve the risk of late miscarriage and preterm births for women with polycystic ovary syndrome (PCOS).

PCOS occurs in 10 to 15 percent of all women. The symptoms are irregular menstrual periods, increased levels of male sex hormones and small ovarian blisters. In addition, many women with PCOS are overweight. Women with PCOS also have an increased incidence of impaired fertility, miscarriages, gestational diabetes, premature births and pre-eclampsia.

“In pregnant women with PCOS, treatment with metformin from the end of the first trimester may reduce the risk of late miscarriages and preterm births,” Eszter Vanky, leader of the research group “Women’s Health—PCOS” at the Norwegian University of Science and Technology (NTNU)’s Department of Clinical and Molecular Medicine, said.

A new article appearing in the Lancet Diabetes & Endocrinology journal presents the results of nearly two decades of research from NTNU and St. Olavs Hospital. Consultant Tone S. Løvvik is the first author, and the study is part of her doctoral work. Sven M. Carlsen is co-supervisor.

However, the research group surprisingly found no reduction of gestational diabetes among this cohort of women with PCOS.

From 2000 to 2017, the research group carried out three controlled studies of nearly 800 pregnant women with PCOS. The studies were conducted at 15 hospitals in Norway, four hospitals in Sweden and one in Iceland. Half of the women were given metformin (2,000 milligrams daily) from first trimester to delivery. The rest of the women were given a placebo.

In addition to a lower risk of late miscarriage and preterm births, the researchers also found that the women who received metformin gained less weight during pregnancy.

A higher level of male sex hormones is associated with several of the symptoms of PCOS. The causes of the condition are not known, but may be related to lifestyle, inheritance and intrauterine fetal life.

The group found no effect on pre-eclampsia, pregnancy-induced high blood pressure or to what extent newborns of women with PCOS needed intensive care.

“Perhaps the most remarkable finding was that metformin had no effect whatsoever on either the incidence or severity of gestational diabetes,” Vanky notes.

Metformin is a well-known drug used in the treatment of type 2 diabetes, and in some countries regarded as equivalent to insulin as a first-line drug therapy for gestational diabetes.

The three studies that form the basis of the conclusion were carried out according to Good Clinical Practice principles and will have an impact on the follow-up and treatment of pregnant women with PCOS and likely also of other pregnant women.

Another part of the study followed up children of mothers with PCOS who used metformin, and a control group that was given a placebo. The result of this survey were recently published by The Lancet Child and Adolescent Health


Filed Under: Drug Discovery

 

Related Articles Read More >

Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE